Article
Cell & Tissue Engineering
Seiko Harada, Yo Mabuchi, Jun Kohyama, Daisuke Shimojo, Sadafumi Suzuki, Yoshimi Kawamura, Daisuke Araki, Takashi Suyama, Masunori Kajikawa, Chihiro Akazawa, Hideyuki Okano, Yumi Matsuzaki
Summary: The study compared gene expression profiles of immature hMSCs and less potent MSCs to explore the molecular mechanisms regulating senescence in hMSCs. It was found that FZD5, a transcription factor expressed specifically in immature hMSCs, plays a crucial role in regulating senescence by promoting proliferation and delaying cell cycle arrest. Controlling FZD5 signaling may offer potential to improve hMSC quality for cell-replacement therapies.
Review
Biochemical Research Methods
Vitali V. Maldonado, Neel H. Patel, Emma E. Smith, C. Lowry Barnes, Michael P. Gustafson, Raj R. Rao, Rebekah M. Samsonraj
Summary: Mesenchymal stem/stromal cells (MSCs) have tremendous potential in regenerative medicine due to their immunomodulatory and regenerative properties. They can be isolated from various tissues and have the properties of multilineage differentiation and paracrine signaling, making them a key candidate for applications in numerous organ systems.
JOURNAL OF BIOLOGICAL ENGINEERING
(2023)
Review
Biotechnology & Applied Microbiology
Yun-Feng Zhou, Di Zhang, Wan-Ting Yan, Kai Lian, Zheng-Zheng Zhang
Summary: This article reviews the therapeutic potential of multipotent stromal cells (MSCs) in repairing meniscal injuries and discusses the avenues for utilizing these cells. The current progress on biomaterial implants is also reviewed.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2022)
Article
Medicine, Research & Experimental
Renata Skovronova, Eleonora Scaccia, Sandra Calcat-i-Cervera, Benedetta Bussolati, Timothy O'Brien, Karen Bieback
Summary: This study indicates that the effects of ASC on immunomodulation and angiogenesis are independent of EV. Specific ASC-EV effects need to be dissected for their use as cell-free therapeutics.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Review
Immunology
Kilian Kelly, John E. J. Rasko
Summary: GvHD is a life-threatening complication of hematopoietic stem cell transplantation, often requiring high-dose corticosteroid treatment. MSCs show promise as a potential therapy due to their immunosuppressive and immunoregulatory effects, but their efficacy may be influenced by donor variability and manufacturing processes.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Cell Biology
Yo Mabuchi, Chikako Okawara, Simon Mendez-Ferrer, Chihiro Akazawa
Summary: This study discusses the heterogeneous nature of mesenchymal cell populations, integrating single-cell analysis data to enhance understanding, while outlining the cell populations involved in the development of myeloproliferative neoplasms.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Raphael Gorodetsky, Wilhelm K. Aicher
Summary: MSCs from different sources can release pro-regenerative and anti-inflammatory factors, with hPSCs from the fresh human placenta being a preferred source for abundant cell harvesting. The f-hPSCs from neonate tissues of the placenta can undergo extended expansion with low risk of senescence, making them competent cells for therapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Immunology
Sanaz Keshavarz Shahbaz, Amir Hossein Mansourabadi, Davood Jafari
Summary: Mesenchymal stem cells (MSCs) have the potential to differentiate into different cell subtypes and have attracted attention in clinical investigations. They can ameliorate immune-related disorders such as graft-versus-host diseases (GVHD) through immunomodulatory effects. Genetic engineering can be used to improve MSC immunosuppressive characteristics and enhance their therapeutic applications.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Gabriella Teti, Eleonora Mazzotti, Valentina Gatta, Francesca Chiarini, Maria Laura Alfieri, Mirella Falconi
Summary: Osteoarthritis (OA) is a chronic degenerative disease characterized by the loss of articular cartilage. Senescent cells in mesenchymal stem/stromal cells (MSCs) isolated from OA joints have been shown to inhibit cartilage regeneration. However, the connection between cellular senescence in MSCs and OA progression is still debated. This study aimed to characterize and compare synovial fluid MSCs (sf-MSCs) from OA joints with healthy sf-MSCs, and investigate the influence of senescence on cartilage repair. The findings demonstrated the presence of senescent sf-MSCs in OA joints, impairing chondrogenic differentiation abilities and potentially impacting OA progression.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Cell & Tissue Engineering
Alison J. Wilson, Emma Rand, Andrew J. Webster, Paul G. Genever
Summary: Many clinical trials involving mesenchymal stem/stromal cells lack comprehensive characterization data of the cellular population, including details on surface marker expression, viability, and differentiation. Functional assessment is very limited and does not always correlate with the likely mechanism of action.
STEM CELL RESEARCH & THERAPY
(2021)
Review
Hematology
Boaz Nachmias, Eran Zimran, Batia Avni
Summary: This paper reviews the clinical experience with the use of MSCs in HSCT and discusses contradictory evidence regarding their effects in hematologic malignancies.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Review
Engineering, Biomedical
Gilad Doron, Johnna S. Temenoff
Summary: This review examines the effects of culture and material properties distinct from traditional planar TCP surfaces on MSC proliferation, surface marker expression, and therapeutic potency. Different properties such as alternative culture formats and culture substrate stiffness can lead to greater cell expansion and improvements in specific therapeutic functionalities, highlighting the importance of culture materials in enhancing clinical-scale manufacture of MSC products.
ADVANCED HEALTHCARE MATERIALS
(2021)
Review
Biochemistry & Molecular Biology
Giuliana Minani Bertolino, Marie Maumus, Christian Jorgensen, Daniele Noel
Summary: Extracellular vesicles (EVs) isolated from induced pluripotent stem cells (iMSCs) show promise in regenerative medicine for the treatment of various diseases. However, the heterogeneity between MSC donors may lead to batch-to-batch variability in the use of EVs as cell-free therapeutic agents.
Article
Pharmacology & Pharmacy
Talagavadi Channaiah Anudeep, Madhan Jeyaraman, Sathish Muthu, Ramya Lakshmi Rajendran, Prakash Gangadaran, Prabhu Chandra Mishra, Shilpa Sharma, Saurabh Kumar Jha, Byeong-Cheol Ahn
Summary: Alopecia, including scarring and non-scarring types, is a common diagnosis in clinical practice. The most prevalent type is non-scarring alopecia, with androgenetic alopecia and alopecia areata being the majority of cases. Traditional treatments have significant downsides, leading to the exploration of regenerative therapies. Growth factor-rich and stem cell-rich treatments have shown potential, but standardization is lacking. Further understanding and standardization of regenerative cellular therapies for hair restoration are needed.
Review
Oncology
Tian Zhou, Zenan Yuan, Jianyu Weng, Duanqing Pei, Xin Du, Chang He, Peilong Lai
Summary: MSC therapy for clinical applications faces challenges due to inconsistent criteria for MSCs identity and their inherited heterogeneity. Strategies have been developed to overcome these challenges with the emergence of advanced biological techniques and substantial improvements in bio-engineered materials.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Letter
Hematology
Annalisa Ruggeri, Liesbeth C. de Wreede, Carlheinz R. Muller, Pietro Crivello, Edouard F. Bonneville, Effie W. Petersdorf, Gerard Socie, Valerie Dubois, Riitta Niittyvuopio, Juha Perasaari, Ibrahim Yakoub-Agha, Jan J. Cornelissen, Lotte Wieten, Tobias Gedde-Dahl, Edouard Forcade, Charles R. Crawley, Steven G. E. Marsh, Virginie Gandemer, Eleni Tholouli, Claude-Eric Bulabois, Anne Huynh, Goda Choi, Eric Deconinck, Maija Itala-Remes, Stig Lenhoff, Mats Bengtsson, Jan-Erik Johansson, Gwendolyn van Gorkom, Jorinde D. Hoogenboom, Luca Vago, Vanderson Rocha, Chiara Bonini, Christian Chabannon, Katharina Fleischhauer
Article
Pathology
Ashley Cartwright, John A. Snowden, Helen Whitehouse, Stuart Scott, Liam Whitby
Summary: This study assessed the implementation of guidelines for Specialist Integrated Haematological Malignancy Diagnostic Services (SIHMDS) in England. The results showed variable implementation across SIHMDS, indicating a need for a more structured framework to improve compliance and achieve quality and equity in haemato-oncology diagnostics.
JOURNAL OF CLINICAL PATHOLOGY
(2023)
Article
Hematology
Sarah Lawless, Simona Iacobelli, Nina Simone Knelange, Patrice Chevallier, Didier Blaise, Noel Milpied, Roberto Foa, Jan J. Cornelissen, Bruno Lioure, Ruben Benjamin, Xavier Poire, Monique C. Minnema, Matthew Collin, Stig Lenhoff, John A. Snowden, Stella Santarone, Keith M. O. Wilson, Fernanda Trigo, Peter Dreger, Lara H. Bohmer, Hein Putter, Laurent Garderet, Nicolaus Kroeger, Ibrahim Yaukoub-Agha, Stefan Schonland, Curly Morris
Summary: This retrospective analysis studied 751 patients with primary plasma cell leukemia (pPCL) undergoing different transplant strategies. The results showed that tandem transplant strategies were more effective than single transplant strategies. Additionally, the disease status at the time of transplant influenced the outcomes.
Article
Hematology
Yves Chalandon, Giulia Sbianchi, Luuk Gras, Linda Koster, Jane Apperley, Jenny Byrne, Urpu Salmenniemi, Henrik Sengeloev, Mahmoud Aljurf, Grzegorz Helbig, Francesca Kinsella, Goda Choi, Peter Remenyi, John A. Snowden, Marie Robin, Stig Lenhoff, Stephan Mielke, Jakob Passweg, Annoek E. C. Broers, Nicolaus Kroeger, Zeynep Arzu Yegin, Sen Mui Tan, Patrick J. Hayden, Donal P. McLornan, Ibrahim Yakoub-Agha
Summary: With the introduction of TKI, the number of allo-HCT for CP CML patients has decreased significantly. The use of 1, 2, or 3 TKI prior to allo-HCT does not affect the overall survival, progression-free survival, relapse incidence, or non-relapse mortality. However, the disease stage and KPS score significantly influence the survival and progression-free survival, emphasizing the importance of careful candidate selection and performing allo-HCT during CP1 phase.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Ingrid Bekono-Nessah, Alex Rosenburg, Christopher T. Bowles, Fernando Riesgo-Gil, Ulrich Stock, Richard R. Szydlo, Mike Laffan, Deepa J. Arachchillage
Summary: Major bleeding and thrombosis significantly increase the 1-year mortality in HVAD patients. Optimal perioperative hemostasis and anticoagulation remain crucial for HVAD patients.
Article
Clinical Neurology
Gavin Brittain, Alasdair J. Coles, G. Giovannoni, Paolo Antonio Muraro, Jacqueline Palace, Jennifer Petrie, Elisa Roldan, N. J. Scolding, John A. Snowden, Basil Sharrack
Summary: In carefully selected patients, autologous HSCT is a safe and highly effective treatment for immune-mediated neurological disorders. Limited understanding has caused confusion, mistrust, and an increase in health tourism.
PRACTICAL NEUROLOGY
(2023)
Article
Biophysics
Anna Waszczuk-Gajda, Luuk Gras, Liesbeth C. de Wreede, Tiarlan Sirait, Arpad Illes, Zubeyde Nur Ozkurt, John A. Snowden, Mutlu Arat, Claude Eric Bulabois, Judith Niederland, Matjaz Sever, Shankara Paneesha, Victoria Potter, Alain Gadisseur, Thomas Chalopin, Gwendolyn Van Gorkom, Joaquin Martinez Lopez, Tessa Kerre, Joanna Drozd-Sokolowska, Kavita Raj, Patrick J. Hayden, Meral Beksac, Ibrahim Yakoub-Agha, Donal P. McLornan, Stefan Schoenland
Summary: The role of high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) in the treatment of myeloma (MM) patients with severe and/or dialysis-dependent renal impairment remains uncertain. We report on the outcomes of 110 patients (median age 57 years) who had become dialysis-dependent pre-ASCT and who underwent a first ASCT between 1997 and 2017. Age at ASCT and response at ASCT (CR/VGPR/PR vs. MR/SD/progression) were significantly associated with better OS and PFS according to multivariate analyses.
BONE MARROW TRANSPLANTATION
(2023)
Review
Infectious Diseases
P. D. E. Miller, S. R. Patel, R. Skinner, F. Dignan, A. Richter, K. Jeffery, A. Khan, P. T. Heath, A. Clark, K. Orchard, J. A. Snowden, T. de Silva
Summary: Haematopoietic stem cell transplant recipients have impaired adaptive immunity against vaccine preventable diseases. Guidelines recommend comprehensive revaccination for these recipients. This position statement aims to provide a standardized revaccination schedule for adult and pediatric HSCT recipients in the UK, considering national vaccine availability and licensing considerations.
JOURNAL OF INFECTION
(2023)
Review
Allergy
Alessandro Bruno, Carmelo Gurnari, Tobias Alexander, John A. Snowden, Raffaella Greco
Summary: VEXAS is a novel disease with a variety of clinical features, mainly affecting men and presenting symptoms in the fifth to sixth decade of life. It has attracted medical interest due to its association with multiple medical conditions. However, its recognition in everyday clinical practice is challenging and requires close collaboration between different medical specialists. The treatment and diagnostic guidelines for VEXAS are exploratory and include rheumatological and supportive care treatments. Allogeneic hematopoietic stem cell transplantation may be curative, but its position in the treatment algorithm is yet to be defined.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2023)
Article
Immunology
Raffaella Greco, John A. Snowden, Nina Simone Knelange, Gloria Tridello, Carlotta Cacciatore, Alienor Xhaard, Fabio Ciceri, Matthew Collin, Christelle Ferra, Ann De Becker, Manuela Badoglio, Dina Averbuch, Tobias Alexander, Per Ljungman, Rafael De la Camara
Summary: This multicenter observational study reported the clinical data on COVID-19 in 11 patients affected by severe autoimmune diseases treated with HSCT. All patients had symptoms during the initial phase of the SARS-CoV-2 infection. Four cases developed lower respiratory tract disease. Hospitalization was required in 6 cases, but none needed ICU admission or ventilation/supplemental oxygen. Different interventions were adopted and all patients survived and resolved the infection at the last follow-up.
JOURNAL OF AUTOIMMUNITY
(2023)
Article
Infectious Diseases
Katharine Pates, Jimstan Periselneris, Mark D. Russell, Varun Mehra, Silke Schelenz, James B. Galloway
Summary: The incidence of Pneumocystis pneumonia (PCP) has been increasing rapidly over the past decade, posing a significant burden on the healthcare system.
JOURNAL OF INFECTION
(2023)
Article
Biochemistry & Molecular Biology
Eleanor Barnes, Carl S. Goodyear, Michelle Willicombe, Charlotte Gaskell, Stefan Siebert, Thushan I. de Silva, Sam M. Murray, Daniel Rea, John A. Snowden, Miles Carroll, Sarah Pirrie, Sarah J. Bowden, Susanna J. Dunachie, Alex Richter, Zixiang Lim, Jack Satsangi, Gordon Cook, Ann Pope, Ana Hughes, Molly Harrison, Sean H. Lim, Paul Miller, Paul Klenerman, Pitch Consortium, Neil Basu, Ashley Gilmour, Sophie Irwin, Georgina Meacham, Thomas Marjot, Stavros Dimitriadis, Peter Kelleher, Maria Prendecki, Candice Clarke, Paige Mortimer, Stacey McIntyre, Rachael Selby, Naomi Meardon, Dung Nguyen, Tom Tipton, Stephanie Longet, Stephen Laidlaw, Kim Orchard, Georgina Ireland, David Thomas, Pamela Kearns, Amanda Kirkham, Iain B. McInnes
Summary: Serological analysis and infection outcomes of 2,686 participants with immune-suppressive diseases who received two COVID-19 vaccines revealed specific clinical phenotypes that might benefit from targeted COVID-19 therapeutic strategies. Some patients failed to develop anti-SARS-CoV-2 antibodies, with the highest vaccine failure rates observed in ANCA-associated vasculitis, hemodialysis, and solid organ transplant recipients. Decreased serological and T cell responses were associated with severe COVID-19. In summary, we identified clinical phenotypes that may benefit from targeted COVID-19 therapeutic strategies.
Article
Hematology
Molly C. Tokaz, Helen Baldomero, Andrew J. Cowan, Wael Saber, Hildegard Greinix, Mickey B. C. Koh, Nicolaus Kroeger, Mohamad Mohty, Sebastian Galeano, Shinichiro Okamoto, Naeem Chaudhri, Amado J. Karduss, Fabio Ciceri, Vergilio Antonio R. Colturato, Selim Corbacioglu, Alaa Elhaddad, Lisa M. Force, Cristobal Frutos, Andres Gomez-De Leon, Nada Hamad, Nelson Hamerschlak, Naya He, Aloysius Ho, Xiao-jun Huang, Ben Jacobs, Hee-Je Kim, Minako Iida, Leslie Lehmann, Regis Peffault de Latour, Mary-Elizabeth M. Percival, Martina Perdomo, Walid Rasheed, Kirk R. Schultz, Adriana Seber, Bor-Sheng Ko, Anderson Joao Simione, Alok Srivastava, Jeff Szer, William A. Wood, Yoshihisa Kodera, Arnon Nagler, John A. Snowden, Daniel Weisdorf, Jakob Passweg, Marcelo C. Pasquini, Anna Sureda, Yoshiko Atsuta, Mahmoud Aljurf, Dietger Niederwieser
Summary: Acute myeloid leukemia (AML) is a fast-progressing and historically challenging disease. Hematopoietic stem cell transplantation (HSCT) is the best treatment option for many patients, but access and utilization on a global scale are unclear. This study aimed to investigate the global use of HSCT in AML and identify areas of need. The study found that AML incidence has increased globally, as has the use of HSCT, particularly allogeneic HSCT. However, there are significant regional variations in HSCT utilization and practices, including differences in graft sources. Further research is needed to understand and address these disparities.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Biophysics
Jesus Duque-Afonso, Juergen Finke, Maud Ngoya, Jacques-Emmanuel Galimard, Charles Craddock, Kavita Raj, Adrian Bloor, Emma Nicholson, Matthias Eder, Orchard Kim, Thomas Valerius, John A. Snowden, Eleni Tholouli, Charles Crawley, Matthew Collin, Keith M. O. Wilson, Alain Gadisseur, Rachel Protheroe, Eva Maria Wagner-Drouet, Bipin N. Savani, Alexandros Spyridonidis, Fabio Ciceri, Arnon Nagler, Mohamad Mohty
Summary: This study compared different conditioning protocols for AML patients with intermediate/poor risk cytogenetics. The results showed that adding a second alkylating agent to the conditioning regimen improved overall survival and reduced non-relapse mortality, with no significant difference in relapse incidence.
BONE MARROW TRANSPLANTATION
(2023)
Article
Hematology
Deepa J. Arachchillage, Anna Weatherill, Indika Rajakaruna, Mihaela Gaspar, Zain Odho, Graziella Isgro, Lenka Cagova, Lucy Fleming, Stephane Ledot, Mike Laffan, Richard Szydlo, Rachel Jooste, Ian Scott, Alain Vuylsteke, Hakeem Yusuff
Summary: Thrombosis and major bleeding are common complications in V-V ECMO patients and significantly increase mortality. Age and elevated creatinine level are associated with increased mortality, while the type of thrombosis has different effects on mortality.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2023)
